GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
GSK has awarded the inaugural £70,000 grant (about $100,000) to the
- Awarding £70,000 ($100,000) grant to the HealthTree Foundation for addressing multiple myeloma care disparities.
- Supports innovative projects targeting underserved communities, enhancing access to education and support.
- None.
Inaugural grant awarded to the
GSK’s grant will help support the
Specifically, the Target the Future grant from GSK will aid in the expansion of two of the following initiatives at the
-
“Black Myeloma Health”: Outreach from the
HealthTree Foundation will expand to spotlight Black patients with multiple myeloma and their experiences through video journaling and distribution of new educational brochures with information about relevant treatments and resources. It will also create distinct communities online for Black patients and caregivers to come together and support each other. -
“HealthTree for Mieloma Multiple”: The organization’s efforts to support multiple myeloma patients will increase through deployment of Spanish-speaking patient navigators who will help people get answers along their treatment journey in their native language. It will also create referral forms in Spanish at clinics and translate existing
HealthTree Foundation materials so more patients can access and understand information relevant to their care.
About the Target the Future Think Tank Challenge
Target the Future is an international, multi-year initiative dedicated to advancing innovation and addressing key needs in the multiple myeloma community. The Think Tank Challenge issued a clarion call for innovative ideas to support patients. GSK assembled a multidisciplinary advisory group of people personally and professionally connected to the multiple myeloma community and evaluated the top 20 submissions from around the world.
Entries came in from patients, caregivers, healthcare professionals, developers, researchers, advocates and non-profits. Following finalist presentations, the panel evaluated ideas on novelty, feasibility to execute and ability to address unmet needs. The panel unanimously voted in favor of the inaugural winner. GSK will share detailed updates as the HealthTree Foundation’s idea comes to life and report on results of this effort within the community.
The Think Tank Challenge will issue the next call for submissions in the second half of 2022. To learn more about GSK’s Target the Future program and ways GSK is collaborating with the community to get ahead of this disease together, please visit https://targetthefuturemm.com.
GSK in Oncology
GSK is focused on maximizing patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody-drug conjugates and cell therapy, either alone or in combination.
About GSK
GSK is a science-led global healthcare company. For further information please visit https://us.gsk.com/en-us/about-us.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK’s Q1 Results for 2022 and any impacts of the COVID-19 pandemic.
Registered in
No. 3888792
Registered Office:
Brentford,
TW8 9GS
View source version on businesswire.com: https://www.businesswire.com/news/home/20220628006164/en/
GSK inquiries:
Media inquiries:
Analyst/Investor inquiries:
Source:
